Panic Disorder

🩺What is Panic Disorder?

The Generalized Anxiety Disorder-7 (GAD-7) is a self-administered screening and severity assessment tool for generalized anxiety disorder, developed by Dr. Robert L. Spitzer and colleagues in 2006. The GAD-7 was derived from the full Patient Health Questionnaire (PHQ) and validated specifically for identifying probable cases of generalized anxiety disorder (GAD) and assessing symptom severity. The GAD-7 asks patients to rate how often they have been bothered by specific anxiety-related problems over the past two weeks, with responses ranging from "not at all" (0) to "nearly every day" (3). Total scores range from 0 to 21, with higher scores indicating greater anxiety severity. The GAD-7 has been validated across multiple populations and clinical settings, demonstrating strong psychometric properties including good internal consistency (Cronbach's alpha = 0.92), test-retest reliability (intraclass correlation = 0.83), and convergent validity with other anxiety measures. At the standard cutoff of 10, the GAD-7 shows sensitivity of 89% and specificity of 82% for generalized anxiety disorder. The GAD-7 also has good sensitivity for detecting panic disorder (sensitivity 74%), social anxiety disorder (sensitivity 72%), and post-traumatic stress disorder (sensitivity 66%). The GAD-7 is recommended by the National Institute for Health and Care Excellence (NICE) for the identification and monitoring of GAD in adults. It is also widely used in primary care settings as a brief anxiety screening instrument that can be completed in under 5 minutes.

📊Clinical Assessment & Risk Scoring

Healthcare professionals use these validated clinical calculators, diagnostic scales, and risk scoring systems to assess the severity, prognosis, or therapeutic dosing requirements for Panic Disorder:

• GAD-7 Anxiety Screening Tool

  The Generalized Anxiety Disorder-7 (GAD-7) is a validated 7-item screening tool used to assess the severity of generalized anxiety disorder and monitor treatment response. It is widely used in primary care, psychiatric, and research settings.

🧬Diagnostic Logic & Scoring Breakdown

The GAD-7 total score is the sum of responses to all 7 questions. Each question is scored 0 ("not at all"), 1 ("several days"), 2 ("more than half the days"), or 3 ("nearly every day"). The minimum total score is 0 and the maximum is 21. A score of 10 or higher is considered the standard cutoff for a positive screen for generalized anxiety disorder. Scores of 5, 10, and 15 represent cut points for mild, moderate, and severe anxiety respectively.

📢Clinical Significance & Implications

The GAD-7 is a widely validated and clinically useful instrument for anxiety screening and severity assessment. Anxiety disorders are among the most prevalent mental health conditions worldwide, affecting approximately 301 million people according to the WHO. The GAD-7 addresses a critical gap in primary care, where anxiety disorders are often underdiagnosed and undertreated. The tool's brevity (7 items, under 5 minutes) makes it practical for busy clinical settings. The GAD-7 demonstrates good sensitivity across multiple anxiety disorders beyond GAD, including panic disorder (74%), social anxiety disorder (72%), and PTSD (66%). This transdiagnostic utility enhances its clinical value as a broad anxiety screening tool. The GAD-7 also correlates well with functional impairment and quality of life measures, and serial assessments can track treatment response over time. NICE guidelines recommend the GAD-7 for identification and monitoring of GAD, and the tool is embedded in the Improving Access to Psychological Therapies (IAPT) programme in the UK. The GAD-7 is available in over 50 languages and has been validated in diverse populations including elderly patients, pregnant women, and patients with comorbid medical conditions.

💡 Clinical Assessment Scenario Example

A 28-year-old male graduate student presents with complaints of persistent worry, difficulty concentrating, and sleep disturbance. He reports feeling "on edge" most days and has difficulty controlling his worry about academic performance, relationships, and health. These symptoms have been present for approximately 8 months and are worsening. His GAD-7 responses: Q1 (nervous): 2 (more than half the days), Q2 (unable to stop worrying): 3 (nearly every day), Q3 (excessive worry): 2 (more than half the days), Q4 (trouble relaxing): 2 (more than half the days), Q5 (restlessness): 1 (several days), Q6 (irritable): 2 (more than half the days), Q7 (fearful): 1 (several days). Total score = 2 + 3 + 2 + 2 + 1 + 2 + 1 = 13/21. This falls in the Moderate anxiety range. Clinical recommendation: initiate CBT and consider SSRI therapy (e.g., sertraline 50 mg daily or escitalopram 10 mg daily). Refer to mental health specialist for comprehensive management. Schedule follow-up in 2 weeks with repeat GAD-7.

💊Common Medications & Interventions

The following pharmacological therapies and substances are commonly referenced or adjusted based on the clinical assessment of Panic Disorder:

🔗Related Diseases & Conditions

These conditions are clinically associated with Panic Disorder through shared risk-scoring calculators and assessment tools:

• Generalized Anxiety Disorder
• Major Depressive Disorder

⚠️Clinical Assessment Pitfalls

• ❌ Mistake: Using GAD-7 as a standalone diagnostic tool

  ✅ Correction: GAD-7 is a screening tool, not a diagnostic instrument. Positive screens require comprehensive clinical evaluation to confirm GAD or identify other anxiety disorders.

• ❌ Mistake: Ignoring somatic symptoms of anxiety

  ✅ Correction: Anxiety often presents with somatic symptoms like palpitations, chest tightness, shortness of breath, and GI distress. These should be evaluated and may require medical workup to rule out organic causes.

• ❌ Mistake: Not screening for comorbid depression

  ✅ Correction: Anxiety and depression frequently co-occur (up to 60% comorbidity). Always administer PHQ-9 alongside GAD-7 for comprehensive mood assessment.

• ❌ Mistake: Applying adult GAD-7 cutoffs to children and adolescents

  ✅ Correction: Modified cutoffs may be needed for pediatric populations. The GAD-7 has been validated in adolescents aged 12-17 with similar psychometric properties.

• ❌ Mistake: Using GAD-7 for short-term anxiety states

  ✅ Correction: GAD-7 assesses symptoms over the past 2 weeks. It is not designed for acute anxiety states or situational anxiety. Use appropriate tools like HAM-A for medication trials or VAS for acute anxiety.

🚑When to Seek Medical Attention

This reference supports clinical assessment of Panic Disorder; it does not replace urgent evaluation. Seek prompt in-person medical care if symptoms are severe, rapidly worsening, or life-threatening, or if you are unsure about a diagnosis or treatment plan. Patients should always consult their physician before starting or changing any therapy.

❓Frequently Asked Questions

📚Evidence-Based References